The case for & against
Bull & Bear analysis
Surgery Partners, Inc. (NASDAQ: SGRY) operates as a leading provider of surgical services across the United States, focusing on outpatient care through a network of ambulatory surgical centers (ASCs) and surgical hospitals. The company specializes in high-quality, elective surgical care, particularly in orthopedics, gastrointestinal (GI), and musculoskeletal (MSK) specialties. Leveraging advancements in surgical technology, including robotics, Surgery Partners aims to capture growth in the evolving healthcare landscape, characterized by increasing patient demand for convenient surgical options and regulatory shifts favoring outpatient procedures.
Bull says
- ↑Strong analyst revisions (score high) underpin confidence in 2026 targets.
- ↑14.6% YoY growth in total joint surgeries; robotics investments fueling momentum.
- ↑Organic expansion: 10 de novo facilities; Q1’26 net revenue $776M (+8% YoY).
- ↑Q1’26 adjusted EBITDA margin 12.6%; operating cash flow $12M vs $6M prior.
- ↑Q1’26 revenue $811M (+3.3% YoY); same-facility revenue growth +4.4%.
- ↑Positive hedge fund interest and undervalued book-to-price support upside.
Bear says
- ↓Elevated leverage raises debt-servicing and refinancing concerns.
- ↓Negative profitability factors; other operating expenses rose to 7.3% of revenue.
- ↓Q1’26 same-facility case growth just 0.6%; weather and mix weigh on volumes.
- ↓Negative earnings yield and zero dividend yield deter income-seeking investors.
- ↓Commercial payer mix at 50%; margin pressure persists on payer shifts.
- ↓Operating cash flow $12M improvement remains vulnerable to volume swings.
Investment themes with SGRY
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- Adjusted EBITDA for the quarter was $102 million. Compared to last year, results reflected the planned impact of payer mix and provider tax items discussed on our fourth quarter call and embedded in our 2026 outlook. Against that backdrop, overall performance came in modestly ahead of expectations and in line with our underlying assumptions for the year.
- Operating cash flow for the quarter was approximately $12 million, an increase from $6 million from the prior year period, reflecting improved underlying performance consistent with typical first quarter seasonality and timing-related movements in working capital.
- We are reiterating our full-year 2026 revenue guidance of $3.35 to $3.45 billion and adjusted EBITDA guidance of at least $530 million.
Bear points
- Other operating expenses were 7.3% of revenue, higher year over year, reflecting the provider taxes we have previously discussed. While these items contributed to margin pressure during the quarter, they were fully contemplated in our internal expectations and full-year outlook.
- Interest expense increased year over year by approximately $7 million, reflecting higher rates following the expiration of our interest rate swap. This increase represented a meaningful cash headwind during the quarter, though it was partially offset by base rate reductions we executed on our credit facility in 2025 and by improved working capital performance.
- Other operating expenses were 7.3% of revenue, higher year over year, reflecting the provider taxes we have previously discussed. While these items contributed to margin pressure during the quarter, they were fully contemplated in our internal expectations and full-year outlook.